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Persistent allergic rhinitis (AR) and asthma constitute a common comorbidity. Combined treat-
ment is recommended by prescribing intranasal plus oral inhaled corticosteroids.
This study was carried out to assess the efficacy of an alternative regimen to treat this
condition.
All recruited patients suffered from persistent AR and asthma. Diagnosis and classification of
AR and asthma were based on international guidelines. The experimental group received flu-
ticasone propionate (FP), 500 mg/day during six weeks, inhaled exclusively through the nose
using a valved large volume spacer attached to a facemask. The comparison group also
received the same dose of orally inhaled FP, during the same time period, plus intranasal
aqueous fluticasone, 200 mg/day. There were no statistical differences between both groups
regarding AR and asthma severity, clinical scores, acoustic rhinometry, lung function, and
FeNO upon admission and during the follow up period. Intragroup analysis demonstrated
a significant improvement for allergic rhinitis and asthma scores as well as for FeNO from
admission to the sixth week (p< 0.01) in both groups.
Results suggest that exclusive nasally inhaled fluticasone propionate should be considered as
an alternative step in the management of patients suffering from AR and asthma comorbidity.
ª 2010 Elsevier Ltd. All rights reserved.3409 9772; fax: þ55 31 3409 9664.
a.ufmg.br (P.A. Camargos).
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Three published studies demonstrated the efficacy of the
simultaneous treatment of persistent allergic rhinitis (AR)
and asthma using the nasal route for inhaled cortico-
steroids.1e3 However this therapeutic strategy was evalu-
ated through conventional clinical and spirometric features
but not with more sophisticated measurements as acoustic
rhinometry and the fraction of exhaled nitric oxide (FeNO).
The objective of this study was to assess the efficacy of
nasally inhaled fluticasone propionate (FP), as a unified
treatment of AR and asthma.
Materials and methods
Patients aged 10e23 years with persistent asthma with
postbronchodilator forced expiratory volume in 1 s (FEV1)
4
response to b-agonists 12% in forced expiratory volume
(FEV1)
4 and persistent allergic rhinitis5 were enrolled. We
excluded non-steroid naı¨ve asthmatic patients, who hadTable 1 Descriptive, clinical and functional characteristics in b
Variables Experimental group Compa
Mean (SD) Mean (
Age (years) 14.8 (2.79) 15.00
Age at asthma onset (years) 4.10 (5.32) 3.94
Age at AR onset (years) 6.00 (5.10) 10.35
AR score
Admission nZ 37 9.20 (3.69) 10.70
Week 2 nZ 36 4.84 (3.09) 5.00
Week 4 nZ 32 5.33 (3.69) 4.35
Week 6 nZ 30 5.18 (4.37) 5.09
Acoustic rhinometrya (cm3)
Admission 10.19 (3.64) 11.20
Week 4 11.11 (2.89) 11.18
Week 6 11.74 (3.89) 11.99
Asthma Score
Admission 10.85 (4.97) 9.00
Week 2 5.52 (3.35) 5.56
Week 4 4.64 (2.78) 6.42
Week 6 4.12 (2.82) 3.36
FEV1(% predicted)
Admission 82.65 (15.30) 85.77
Week 4 100.7 (26.53) 101.19
Week 6 97.23 (25.38) 93.96
FEF 25e75% (%predicted)
Admission 51.46 (22.33) 47.60
Week 4 60.08 (27.66) 70.80
Week 6 63.65 (36.94) 75.4
FeNO (ppb)
Admission 17.7 (14.08) 24.1
Week 4 11.8 (14.44) 7.0
Week 6 9.5 (6.11) 10.4
NAZ not applicable.
a Rightþ left acoustic rhinometry.any exacerbations in the four weeks preceding the admis-
sion, patients suffering from severe persistent asthma
(e.g., prebronchodilator FEV1 60% predicted), who used
systemic steroids, intranasal corticosteroids, topic vaso-
constrictors, anti-histamine agents or leukotriene modifier
in the last 30 days, specific desensitization in the previous
three months upon admission, tobacco smokers, upper
respiratory tract infection, and chronic concurrent
diseases.
AR was assessed by Wilson’s clinical score.6 By adding up
we reached the final score, characterizing as mild,
moderate and severe based on the scores of lower than 6,
7e12 and 13e18, respectively. Likewise, the score
described by Rosier et al was used to classify asthma
severity,7 as follows: mild, moderate and severe when the
score add up to 2e8, 9e14 and 15e19 points, respectively.
The study lasted six weeks. Pulmonary function testing
was performed and interpreted according to the American
Thoracic Society (ATS) criteria using the Stead-Wells DS II
PLUS 10 L spirometer (Warren-Collins, USA). FeNO was
measured by using online single breath method with Nitricoth groups upon admission and during the follow up.
rison group p-Value Difference 95% CI
SD)
(4.54) 0.90 NA NA
(4.39) 0.92 NA NA
(23.16) 0.88 NA NA
(2.82) 0.17 1.50 3.71 to 0.71
(2.63) 0.87 0.16 2.10 to 1.78
(2.76) 0.41 0.98 1.38 to 3.33
(2.84) 0.94 0.09 5.75 to 5.93
(3.59) 0.40 1.01 3.42 to 1.41
(3.42) 0.95 0.07 1.71 to 1.57
(2.87) 0.85 0.25 2.87 to 2.37
(3.93) 0.22 1.85 1.17 to 4.87
(3.70) 0.97 0.04 2.41 to 2.33
(3.87) 0.14 1.78 4.14 to 0.58
(2.42) 0.47 0.76 1.24 to 2.76
(9.90) 0.47 3.12 11.87 to 5.64
(19.67) 0.95 0.49 17.35 to 16.37
(16.93) 0.71 3.37 13.38 to 19.92
(19.82) 0.63 3.86 10.31 to 18.03
(23.34) 0.34 10.72 29.09 to 7.65
(33.76) 0.56 11.75 38.51 to 15.02
(20.42) 0.31 6.4 17.93 to 5.13
(7.50) 0.33 4.8 3.61 to 13.22
(7.37) 0.85 0.9 5.92 to 4.12
Table 2 Intragroup analysis comparing mean values of clinical and functional variables at admission and at the 6th week in
both groups.
Variables Mean difference p-Value
Experimental group Comparison group Experimental group Comparison group
AR score (points) 4.61 5.41 <0.01 <0.01
Righteleft acoustic rhinometry (cm3) 1.5 1.06 0.06 0.17
Asthma score (points) 6.36 5.08 <0.01 <0.01
FEV1 (% predicted) 12.31 4.87 0.02 0.34
FEF25e75% (% predicted) 14.33 27.88 0.06 0.02
FeNO (ppb) 8.29 17.50 <0.01 <0.01
Nasally inhaled steroid for rhinitis and asthma 1579Oxide Analyzer, model 280 (Sievers Inc., USA) according to
ATS/European Respiratory Society8 recommendations.
Acoustic rhinometry (Eccovision, USA) was carried out
according to the Standardization Committee on Acoustic
Rhinometry Guidelines9 to measure nasal cavity volume,
calculated from the area-distance expressed in cm3. In the
final analysis we considered the summation of the values of
both nostrils.10
Patients were randomly assigned in two groups: the
experimental one was treated with exclusive nasal inhala-
tion of fluticasone propionate (FP) (Flixotide, Glax-
oSmithKline, Brazil, 250 mg/puff), 500 mg/day, through
a large volume pear shaped valved spacer (Flumax, Flu-
max Medical Equipments, Brazil) attached to a facemask.
After each puff subjects repeatedly inhaled FP deeply
through their noses for 30 s keeping their mouth closed. The
comparison group received the dual conventional treat-
ment, i.e., the same dose of orally inhaled FP through the
mouthpiece of the same spacer to treat asthma and,
aqueous intranasal fluticasone (Flixonase, GlaxoSmithK-
line, Brazil, 200 mg/day) for AR. The study protocol and the
written consent were approved by the local ethics
committee.
Descriptive and analytical statistics, as well as the
difference between clinical scores, functional parameters
were calculated for each group by paired t-Student test
upon admission and on the last visit. For these intra-group
comparisons, statistically significant differences were
evaluated after a Bonferroni correction, which yielded a p-
value of 0.012 for the differences observed, considering
four comparison pairs.
Results
Among the 37 recruited patients 30 of them completed the
study protocol. Upon admission and during the follow up
there were no statistically significant differences between
the two groups regarding the studied variables (see
Table 1). From admission to the sixth week, FeNO levels
dropped 46.8% and 56.7% and acoustic rhinometry values
increased 15.2% and 12% in the experimental and compar-
ison group, respectively. There were no significant differ-
ences when data were re-analysed after exclusion of drop
outs.
Table 2 shows intragroup analysis comparisons between
the initial and final mean values of clinical scores, acoustic
rhinometry, pulmonary function tests and FeNO. Therewere an evident improvement for all of these outcomes,
but a statistically significant difference was observed only
for AR and asthma scores, and FeNO.
Discussion
Studies that assessed the efficacy of nasally inhaled corti-
costeroids for the concomitant treatment of AR and asthma
are scarce1e3 and none of them included acoustic rhinom-
etry and FeNO measurements.
In two studies, patients were treated previously for
asthma, differently to the present one. Pedersen et al
assessed 24 children receiving budesonide inhaled nasally
through a non-commercialized nozzle during three
weeks.1 Compared with placebo, budesonide treatment
resulted in a significant reduction in nasal and asthma
symptoms, and in an increase of peak expiratory flow and
nasal peak inspiratory flow (p-values< 0.05). Among 75
patients evaluated by Camargos et al, 38 received nasally
inhaled beclometasone2; the control group used aqueous
beclometasone for AR.2 There were also no statistically
significant differences between both groups
(p-values 0.11).
In the third one 60 steroid-naive patients were treated
with nasally or orally inhaled FP, while the comparison
group received 0.9% saline solution for AR.3 Again, there
were no statistically significant differences in asthma
outcomes (p-values 0.15), but the intervention group had
significant improvements in AR symptoms when compared
to comparison group (almost all p-values 0.01).
Due to small sample size, our study is clearly under-
powered (power average was approximately 10% for the
studied outcomes). However, clinical and spirometric find-
ings are in agreement with the results observed in the three
above mentioned studies. Moreover, our results were rein-
forced by the findings of the two new measurements, i.e.,
acoustic rhinometry and FeNO which favored this alterna-
tive way to treat AR-asthma comorbidity. Finally, nasally
inhaled corticosteroid has the advantage of treating it with
one single medicine in a rational and low cost manner.Ackowledgements
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